Summary
Merck & Co., Inc. reported $47.3 billion in worldwide sales for 2012, a slight 2% decrease from 2011, impacted by the U.S. patent expiration of Singulair. Despite this, the company demonstrated resilience with a 1% sales increase excluding foreign exchange impacts, driven by growth in key products like Januvia, Janumet, Gardasil, and Victrelis. Merck continued to focus on cost management, reducing operating expenses, and advancing its robust research and development pipeline, with several key drug candidates under regulatory review and in late-stage development. The company also highlighted strategic growth initiatives, including geographic expansion into high-growth markets, expansion into complementary Animal Health and Consumer Care businesses, and continued investment in innovation. Despite facing pricing pressures globally and the ongoing impact of healthcare reform, Merck demonstrated strong operational execution and maintained its commitment to returning capital to shareholders through dividends and share repurchases. The company also addressed significant legal settlements, notably the ENHANCE litigation, which impacted 2012 earnings but was covered by insurance recoveries.
Financial Highlights
53 data points| Revenue | $47.27B |
| Cost of Revenue | $16.45B |
| Gross Profit | $30.82B |
| R&D Expenses | $8.17B |
| SG&A Expenses | $12.78B |
| Interest Expense | $714.00M |
| Net Income | $6.17B |
| EPS (Basic) | $2.03 |
| EPS (Diluted) | $2.00 |
| Shares Outstanding (Basic) | 3.04B |
| Shares Outstanding (Diluted) | 3.08B |
Key Highlights
- 1Worldwide sales of $47.3 billion for 2012, a 2% decrease from 2011, primarily due to the Singulair U.S. patent expiration.
- 2Sales excluding foreign exchange increased by 1%, indicating underlying operational strength driven by key products like Januvia and Gardasil.
- 3Significant R&D pipeline advancement with multiple drug candidates under regulatory review and in Phase III development.
- 4Strategic focus on cost management led to reduced operating expenses and achievement of merger-related cost savings.
- 5Continued investment in high-growth emerging markets, with China showing a notable 25% sales increase.
- 6Animal Health and Consumer Care segments showed solid growth, contributing positively to overall performance.
- 7The company incurred a $493 million charge for the ENHANCE litigation settlement in 2012, partially offset by insurance recoveries.